CLSD: Large pot of gold behind multiple walls of defense

3 months ago

BiotechBonanza

"CLSD: Exploring strategic alternatives after firing all staff. Owns royalty rights to FDA-approved XIPERE (Bausch) & ABBV/RGNX gene therapy partnership. ABBV upgraded opportunity from 'small' to 'highly transformative.' BUT: sold first $106M proceeds to HCR, ~$3-10M net debt, no institutional holders, patents expire risk. Paths to multibagger or zero."

Related Stocks